The Global Celecoxib Market is poised to value over USD 3.2 billion by 2028 end at a CAGR of over 8% during the forecast period 2022 to 2028.
Celecoxib capsules (patent brand name: CELEBREX) are a new generation of nonsteroidal anti-inflammatory and analgesic drugs that work primarily by inhibiting the production of prostaglandins via the selective inhibition of coX-2 (COX-2). The medication is used to treat osteoarthritis and rheumatoid arthritis in adults, and it has fewer gastrointestinal side effects than traditional nonsteroidal anti-inflammatory drugs. The number of patients with arthritis in mainland China exceeds a huge number, accounting for more than 10% of the total population. The incidence of arthritis increases with age, and the number of patients continues to rise. The burden of chronic diseases is expected to rise by 40% as the population ages. Anti-inflammatory and anti-rheumatic drugs will experience rapid growth as the population ages. Xibu is widely used in clinical practise worldwide, whether as a prescription or non-prescription drug. Celixib is currently the best-selling drug on the international market. The celixib market will expand steadily in the coming years. The global celecoxib market is currently dominated by Pfizer, which has established an oligopoly. Celecoxib was found to be no more effective for pain relief than other NSAIDs in comparative trials. And, after it was revealed that the CLASS study results had been tampered with, it became clear that celecoxib had no discernible advantage in terms of serious gastrointestinal complications. An increase in Cox-2 inhibitor prescriptions, owing to their reputation for tolerability, resulted in an increase in the absolute number of cases of gastrointestinal haemorrhage. Cardiovascular events occurred two to three times more frequently with celecoxib than with placebo in a trial focusing on the prevention of colorectal polyps. Another trial found no statistically significant difference. Overall mortality was higher with celecoxib than with placebo in a trial involving patients with Alzheimer’s disease. The difference was comparable to what was seen in placebo-controlled trials of rofecoxib for Alzheimer’s disease.
The astute research report on Celecoxib market provides intricate details for analyzing appropriate parameters and valuable insights. The report offers extensive information about this business to help bring forth the growth potential of the market across various segments and provides the clients with a comprehensive analysis of factors like market size, market growth trends, competitive landscape, product utilization, regional growth prospects, and application potential, etc. The data provided in the report has been gathered from a wide variety of sources by using primary and secondary research. This Celecoxib research report also provides crucial insights into consumer behaviour, brand positioning, pricing analysis, and key player strategies. The market overview included in the Celecoxib research report incorporates critical factors procured from industry analysts, prominent players as well as trade and industrial organizations.
The report on Celecoxib market offers up-to-date information on the factors impeding the market growth which shall provide vendors with crucial insights into understanding the market dynamics thereby aiding the clients to sketch out a better business strategy. These factors will help them identify market growth opportunities. Furthermore, FutureWise research analysts provide timely assistance to their customers in understanding eccentric market parameters more effectively thereby leading to better decision-making.
Get a Sample of the Celecoxib Market Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=10625&page=requestsample
The Celecoxib market research report is segmented – by type, by application, and by region. It also consists of insights regarding the revenue value and sales volume during the forecasted timeframe of 2022 to 2028.
Celecoxib Market Segmentation:
By Type
50mg
100mg
200mg
400mg
By Application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Celecoxib Market Regional Analysis:
The report provides a complete evaluation of the potential amplification of the Celecoxib Market in pivotal geographic regions such as North America, Asia Pacific, Europe, Latin America and Middle East & Africa.
Competitive Landscape:
Some of the key market players are
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
FutureWise Key Takeaways:
Growth prospects
SWOT analysis
Key market trends
Key data-points affecting market growth
Objectives of the Study:
To provide an extensive analysis of the global Celecoxib market by type, by application, and by region
To carter complex data and information on the characteristics influencing the market growth (drivers, restraints, opportunities, and industry-specific restraints)
To predict and assess micro-markets and the overall market
To anticipate the market size, in key geographical regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the Middle East and Africa
To estimate and inspect competitive landscape mapping- technological advancements, product launches, mergers and expansions
Flexible Delivery Model:
Our delivery model is flexible, so you can suggest changes to the content/scope as per your requirement
With purchase of any license of the report the customization Mobility Care offered is free of charge
You can directly forward your requirements/changes to the current table of content to: sales@futurewiseresearch.com
About FutureWise Market Research:
We specialize in high-growth niche market research, offering flexibility, agility, and customized solutions for our clients. By providing our clients with market insights and consulting services, we ensure they stay on top of their industries for years to come.
FutureWise Market Research
Vinay T – Head of Business Development
Email: sales@futurewiseresearch.com
UK: +44 141 628 9353 | USA: +1 347 709 4931
Website: www.futurewiseresearch.com
